Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent
Authors:
- 2 Adiba Sultana12S2 Adiba Sultana1
- Giovanni Battista Migliori3GMGiovanni Battista Migliori3
- 4 Lia D’aMbrosio4D4 Lia D’aMbrosio
- José-María García-García5JGJosé-María García-García5
- Denise Rossato Silva6DSDenise Rossato Silva6
- Luis Adrian Rendon5LRLuis Adrian Rendon5
- Luigi R Codecasa7LCLuigi R Codecasa7
- Francois-Xavier Blanc8FBFrancois-Xavier Blanc8
- Simon Tiberi9STSimon Tiberi9
- 11 Catherine W M Ong101O11 Catherine W M Ong10
- Courtney Heffernan13CHCourtney Heffernan13
- Giovanni Sotgiu14Giovanni Sotgiu14
Open Access
- 18 September 2024
- journal article
- research article
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (4) , e20240082
Abstract
Objective: Many biologic agents cause some degree of immunosuppression, which can increase the risk of reactivation of tuberculosis infection (TBI). This risk is variable between individual biologics. We aimed to assess current (and recommended) clinical practice of TBI screening and treatment among patients initiating treatment with biologic agents. Methods: An online questionnaire was distributed via email to members of the Global Tuberculosis Network and associated professional organisations to seek insights into the screening for and treatment of TBI in patients treated with biologics. Results: A total of 163 respondents in 27 countries answered at least one question. For all biologics described in the questionnaire, respondents advised increasing screening relative to current practice. Observed and supported TBI screening rates in patients treated with TNF-a inhibitors were high, especially for older TNF-a inhibitors. Most participants supported TBI screening in patients treated with B- or T-cell inhibitors but not in those treated with interleukin inhibitors. Guideline awareness was higher for TNF-a inhibitors than for other biologic classes (79% vs. 34%). Conclusions: Although respondents stated that TBI screening rates are lower than what they consider ideal, there was a tendency to recommend TBI screening in patients treated with biologics not known to be associated with an increased risk of TBI. As a result, there is a potential risk of over-screening and over-treatment of TBI, potentially causing harm, in patients treated with biologics other than TNF-a inhibitors. There is a need to research the risk of TBI associated with biologics and for guidelines to address the spectrum of TBI risk across all types of biologics.Keywords
This publication has 32 references indexed in Scilit:
- Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha BiologicalsPneumologie, 2021
- Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 InhibitionInfectious Disease Clinics of North America, 2020
- Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasisBritish Journal of Dermatology, 2019
- Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real‐world clinical experience from IndiaInternational Journal of Rheumatic Diseases, 2018
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)Clinical Microbiology and Infection, 2018
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)Clinical Microbiology and Infection, 2018
- Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological TreatmentArchivos de Bronconeumología, 2016
- Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practiceAutoimmunity Reviews, 2015
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registryArthritis & Rheumatism, 2009
- Cannabinoids2007